1. Home
  2. ICUCW vs CMMB Comparison

ICUCW vs CMMB Comparison

Compare ICUCW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • CMMB
  • Stock Information
  • Founded
  • ICUCW N/A
  • CMMB 2004
  • Country
  • ICUCW United States
  • CMMB Israel
  • Employees
  • ICUCW 12
  • CMMB N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICUCW Health Care
  • CMMB Health Care
  • Exchange
  • ICUCW Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • ICUCW N/A
  • CMMB 37.3M
  • IPO Year
  • ICUCW 2021
  • CMMB N/A
  • Fundamental
  • Price
  • ICUCW $0.04
  • CMMB $1.97
  • Analyst Decision
  • ICUCW
  • CMMB Strong Buy
  • Analyst Count
  • ICUCW 0
  • CMMB 2
  • Target Price
  • ICUCW N/A
  • CMMB $7.50
  • AVG Volume (30 Days)
  • ICUCW N/A
  • CMMB 82.4K
  • Earning Date
  • ICUCW N/A
  • CMMB 03-06-2025
  • Dividend Yield
  • ICUCW N/A
  • CMMB N/A
  • EPS Growth
  • ICUCW N/A
  • CMMB N/A
  • EPS
  • ICUCW N/A
  • CMMB N/A
  • Revenue
  • ICUCW N/A
  • CMMB N/A
  • Revenue This Year
  • ICUCW N/A
  • CMMB N/A
  • Revenue Next Year
  • ICUCW N/A
  • CMMB N/A
  • P/E Ratio
  • ICUCW N/A
  • CMMB N/A
  • Revenue Growth
  • ICUCW N/A
  • CMMB N/A
  • 52 Week Low
  • ICUCW N/A
  • CMMB $0.55
  • 52 Week High
  • ICUCW N/A
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • CMMB 56.98
  • Support Level
  • ICUCW N/A
  • CMMB $2.02
  • Resistance Level
  • ICUCW N/A
  • CMMB $2.15
  • Average True Range (ATR)
  • ICUCW 0.00
  • CMMB 0.12
  • MACD
  • ICUCW 0.00
  • CMMB -0.01
  • Stochastic Oscillator
  • ICUCW 0.00
  • CMMB 69.57

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: